Cold sore virus turned cancer assassin shows promise in tough breast cancer
NCT ID NCT02779855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether injecting a modified herpes virus (T-VEC) directly into tumors, alongside standard chemotherapy before surgery, could better eliminate triple negative breast cancer. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone, and may also help the immune system attack the tumor. The trial enrolled 50 women with early-stage triple negative breast cancer to find the safest dose and measure how many had no cancer left at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States